Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
暂无分享,去创建一个
Rupert Lanzenberger | Andreas Hahn | Oskar Hansson | Jonas Jögi | Maria Erlandsson | A. Hahn | R. Lanzenberger | M. Schain | O. Hansson | Ruben Smith | O. Strandberg | J. Jögi | Douglas Hägerström | G. M. James | Olof T Strandberg | Ruben Smith | Martin Schain | Petter Sjölin | Gregory M James | Douglas Hägerström | Tomas G Olsson | P. Sjölin | M. Erlandsson | Tomas G. Olsson | Jonas Jögi
[1] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[2] G. V. Van Hoesen,et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.
[3] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] Richard E Carson,et al. Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] A. Probst,et al. The Neuropathological Spectrum of Neurodegenerative Tauopathies , 2003, IUBMB life.
[8] Christopher C Rowe,et al. Tau imaging: early progress and future directions , 2015, The Lancet Neurology.
[9] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[10] C. Jack,et al. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias , 2014, Alzheimer's Research & Therapy.
[11] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[12] S. Gauthier,et al. Developments in Tau PET Imaging , 2014, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[13] C. Hock,et al. ELISA-Quantitation of Phosphorylated Tau Protein in the Alzheimer’s Disease Brain , 1999, European Neurology.
[14] Victor W Pike,et al. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.
[15] Bradford C. Dickerson,et al. Tau PET imaging in aging and early Alzheimer's disease , 2015 .
[16] D. J. Brooks,et al. Tau imaging in neurodegenerative diseases , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Ming-Rong Zhang,et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.
[18] Isidre Ferrer,et al. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. , 2014, Journal of neuropathology and experimental neurology.
[19] Ramin V. Parsey,et al. Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [11C]DASB and Positron Emission Tomography , 2006, Biological Psychiatry.
[20] R. Vandenberghe,et al. Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807 , 2016, Molecular imaging.
[21] Sylvain Houle,et al. Positron Emission Tomography Quantification of [11C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] M. Mintun,et al. Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[23] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[24] Roger N. Gunn,et al. Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.
[25] Gunnar Antoni,et al. Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology , 2016, The Journal of Nuclear Medicine.
[26] Ramin V. Parsey,et al. Optimal Metabolite Curve Fitting for Kinetic Modeling of 11C-WAY-100635 , 2007, Journal of Nuclear Medicine.
[27] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[28] J. Hirvonen,et al. Population-Based Input Function Modeling for [18F]FMPEP-d 2, an Inverse Agonist Radioligand for Cannabinoid CB1 Receptors: Validation in Clinical Studies , 2013, PloS one.
[29] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[30] H. Arai,et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[31] V. Bettinardi,et al. Physical performance of the new hybrid PET∕CT Discovery-690. , 2011, Medical physics.
[32] I Litvan,et al. Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.
[33] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[34] Bradley T. Hyman,et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.
[35] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[36] K. Blennow,et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.